A Study of Talazoparib Given With Enzalutamide in Men Who Have Metastatic Castration-Resistant Prostate Cancer (mCRPC)
A Study of Talazoparib Given With Enzalutamide in Men Who Have Metastatic Castration-Resistant Prostate Cancer (mCRPC). TALAPRO 2: A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Talazoparib With Enzalutamide in Metastatic Castration Resistant Prostate Cancer.
Category & Conditions: Cancer
Medicine: Talzenna (talazoparib)
ClinicalTrials.gov Identifier (NCT): NCT03395197
Protocol ID: C3441021
PrintDownloadOpen Plain Language Summary Result: Click here